논문실적
Home › 연구실적 › 논문실적
- 320Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19
Cho YS, Shin JG · Transl Clin Pharmacol. 30(1):24-36 / 2022.03 · 2022 cPMTb
- 319Delineation of the molecular mechanisms underlying Colistin-mediated toxicity using metabolomic and transcriptomic analyses
Long NP, Oh JH, Park SM, Yen NTH, Phat NK, Cho YS, Kim HM, Yoon SJ, Shin JG, Kim DH · Toxicol Appl Pharmacol. 15:439:115928 / 2022.03 · 2022 cPMTb
- 318Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research
Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL, Kim EY, Cho YS, Babaoglu MO, Shin JG · Br J Clin Pharmacol. 88(3):1159-1169 / 2022.03 · 2022 cPMTb
- 317Para-aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research
Parvez MM, Kalkisim S, Nguyen PTT, Jung JA, Park JK, Ghim JL, Kim EY, Cho YS, Babaoglu MO, Shin JG · Br J Clin Pharmacol. 88(3):1159-1169 / 2022.03 · 2022 cPMTb
- 316The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats
Abed AF, Jarrar YB, Al-Ameer HJ, Al-Awaida W, Lee SJ · Curr Pharm Des. 28(4):324-330 / 2022.02 · 2022 cPMTb
- 315Molecular toxicological alterations in the mouse hearts induced by sub-chronic thiazolidinedione drugs administration
Jarrar YB, Jarrar O, Abaalkhail SJ, Kalloush HM, Naser W, Zihlif M, Shhab MA, Madani AE, Jamous Y, Lee SJ · Fundam Clin Pharmacol. 36(1):143-149 / 2022.02 · 2022 cPMTb
- 314Demand for Pharmacogenomics and Personalized Medicine in the United Arab Emirates
Jarrar Y, Lee SJ · J Pers Med. 12(1):104 / 2022.01 · 2022 cPMTb
- 313Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis
Cho YS, Bae KS, Choi SC, Cho JM, Lim HS · Clin Ther. 44(1):67-80.e1 / 2022.01 · 2022 cPMTb
- 312The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population
Pham VH, Nguyen VL, Jung HE, Cho YS, Shin JG · BMC Med Genomics 3;15(1):3 / 2022.01 · 2022 cPMTb
- 311Molecular perturbations in pulmonary tuberculosis patients identified by pathway-level analysis of plasma metabolic features
Long NP, Heo DY, Park SO, Yen NTH, Cho YS, Shin JG, Oh JY, Kim DH · PLoS One.24;17(1):e0262545 / 2022.01 · 2022 cPMTb
- 310Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis
Cho YS, Bae KS, Choi SC, Cho JM, Lim HS · Clin Ther. 44(1):67-80.e1 / 2022.01 · 2022 cPMTb
- 309A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction
Long NP, Phat NK, Yen NTH, Park SO, Park YM, Cho YS, Shin JG · Tuberculosis (Edinb). 131:102138 / 2021.12 · 2021 cPMTb
- 308Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis
Cho YS, Jang TW, Kim HJ, Oh JY, Lee HK, Park HK, Ghim JL, Long NP, Park YM, Choi YK, Phuong NTT, Shin JG · J Clin Pharmacol. 61(12):1567-1578 / 2021.12 · 2021 cPMTb
- 307Advances in Personalized Medicines along with Functional Genomics and Pharmacogenomics
Lee SJ · J Pers Med. 22;11(10):941 / 2021.09 · 2021 cPMTb
- 306Metabolomics-guided global pathway analysis reveals better insights into the metabolic alterations of breast cancer
Long NP, Heo DY, Kim HY, Kim TH, Shin JG, Lee AB, Kim DH · J Pharm Biomed Anal. 5:202:114134 / 2021.08 · 2021 cPMTb